Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation

Zoetis Inc. the world’s leading animal health company, today announced it has entered into a definitive agreement with Neogen Corporation (NASDAQ: NEOG) (“Neogen”) to acquire Neogen’s animal genomics business for $160 million, subject to customary closing adjustments. This acquisition aligns directly with Zoetis’ strategy to drive future livestock innovation through genomics, reinforcing its commitment to livestock producers worldwide and advancing its Precision Animal Health portfolio. By integrating Neogen’s genomic technologies and data solutions, Zoetis is expanding its capabilities to deliver predictive insights, individualized care, and greater value to customers across major livestock and companion animal species.

Neogen’s genomics business serves customers in more than 120 countries through its five laboratories in the United States, Brazil, Australia, China and the United Kingdom, as well as an office location in Canada. The business leverages a comprehensive genotyping platform of fixed array and sequencing technologies, as well as software solutions that empower customers to make informed and data-driven decisions. The business is a leader in U.S. beef and dairy genomics, and its cutting-edge technologies enable highly accurate, scalable genetic testing and deeper insights into animal health, productivity and sustainability.

“The addition of Neogen’s genomics business strengthens our commitment to advancing animal health through innovation, data, and technology,” said Jamie Brannan, Chief Commercial Officer at Zoetis. “As we continue to grow our leading innovative solutions in Precision Animal Health, this acquisition brings complementary capabilities that expand predictive insights and individualized care, enabling us to deliver added value to customers. Together, we are shaping the future of animal health, empowering customers with the tools they need to support healthier animals and sustainable livestock production globally.”

The deal is subject to customary closing conditions and the satisfaction of regulatory requirements, and Zoetis expects to complete the acquisition in the second half of calendar year 2026. Zoetis is committed to a seamless integration, supporting continuity for colleagues and customers, and building on Neogen’s legacy of innovation in genomics.

Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.

Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.